<DOC>
	<DOCNO>NCT00632970</DOCNO>
	<brief_summary>This program design study efficacy , safety , lipid effect tolerability raltegravir compare lopinavir/ritonavir , patient HIV-I infection receive prior antiretroviral therapy . All patient receive concomitant therapy Truvada . It hypothesize ( 1 ) raltegravir regimen similar efficacy term viral suppression well increase CD4 cell count ( 2 ) raltegravir significantly less impact plasma lipid , lipoproteins lipoprotein subtypes , compare lopinavir/ritonavir .</brief_summary>
	<brief_title>Raltegravir vs. Lopinavir/Ritonavir , Both Combination With Truvada , HIV+ Treatment Naive Individuals</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Documented HIV infection confirm western blot HIV RNA . 2 . At least 18 year age . 3 . Less 1 week prior antiretroviral therapy . 4 . In opinion investigator , patient clinically stable . Patients may chronic suppressive therapy opportunistic infection MAC CMV . 5 . Patients reproductive potential agree use acceptable method birth control throughout study . Acceptable method include intrauterine device ( IUD ) , diaphragm spermicide , condom , abstinence . 6 . HIV RNA &gt; 5000 copies/ml . No restriction CD4 cell count . 7 . A negative urine pregnancy test day initiation therapy . 1 . Prior treatment &gt; 1week antiretroviral therapy . 2 . Patient require anticipated require prohibit medication note protocol . 3 . HIV RNA &lt; 5000 prior receive therapy . 4 . Baseline resistance study regimen drug genotype testing . 5 . Patients acute hepatitis due cause clinically significant chronic liver disease . 6 . Patient severe renal insufficiency define calculated creatinine clearance time screen &lt; 30mL/min , base CockcroftGault equation follow ( 0.85X value female ) : Clcr ( mL/min ) = ( l40age ) x weight ( kg ) 72 x serum creatinine ( mg/dL ) . 7 . Patient condition ( include limit alcohol substance abuse ) opinion investigator would interfere patient compliance safety . 8 . A female patient pregnant , breastfeeding , expect conceive donate egg study ; male patient plan impregnate provide sperm donation study exclude . 9 . Inability obtain sign informed consent patient age 18 old . 10 . Patient significant hypersensitivity contraindication component study drug . 11 . Patients treat hyperlipidemia per NCEPIII guideline patient currently receive lipidlowering therapy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>Lopinavir</keyword>
</DOC>